Preclinical Evaluation and Quantification of <sup>18</sup>F-Fluoroethyl and <sup>18</sup>F-Fluoropropyl Analogs of SCH442416 as Radioligands for PET Imaging of the Adenosine A<sub>2A</sub> Receptor in Rat Brain.

Khanapur, Shivashankar; van Waarde, Aren; Dierckx, Rudi A J O; Elsinga, Philip H; Koole, Michel J B · J Nucl Med · 2017

basic_science · Level V

Where this comes from

Abstract

The cerebral adenosine A<sub>2A</sub> receptor is an attractive therapeutic target for neuropsychiatric disorders. <sup>18</sup>F-fluoroethyl and <sup>18</sup>F-fluoropropyl analogs of <sup>18</sup>F-labeled pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (SCH442416) (<sup>18</sup>F-FESCH and <sup>18</sup>F-FPSCH, respectively) were developed as A<sub>2A</sub> receptor-specific PET ligands. Our aim was to determine an appropriate compartmental model for tracer kinetics, evaluate a reference tissue approach, and select the most suitable PET ligand. <b>Methods:</b> A 90-min dynamic PET scan with arterial blood sampling and metabolite analysis was acquired for 22 healthy male Wistar rats starting at the time of <sup>18</sup>F-FESCH (<i>n</i> = 12) and <sup>18</sup>F-FPSCH (<i>n</i> = 10) injection. For each tracer, half the animals were vehicle-treated whereas the other half were pretreated with the A<sub>2A</sub> receptor-selective antagonist KW-6002, inducing full blocking. Regional tissue total volume of distribution (V<sub>T</sub>) was estimated by 1- and 2-tissue-compartment modeling (1TCM and 2TCM, respectively) and Logan graphical analysis. Midbrain, cerebellum, and hippocampus were evaluated as the reference region by comparing baseline V<sub>T</sub> with V<sub>T</sub> under full blocking conditions and comparing striatal nondisplaceable binding potential (BP<sub>ND</sub>) using a simplified reference tissue model (SRTM) with distribution volume ratio minus 1 (DVR - 1) for 60- and 90-min scans. <b>Results:</b> On the basis of the Akaike information criterion, 1TCM and 2TCM were the most appropriate models for <sup>18</sup>F-FPSCH (baseline striatal V<sub>T</sub>, 3.7 ± 1.1) and <sup>18</sup>F-FESCH (baseline striatal V<sub>T</sub>, 5.0 ± 2.0), respectively. Baseline striatal V<sub>T</sub> did not significantly differ between tracers. After pretreatment, striatal V<sub>T</sub> was reduced significantly, with no significant decrease in hippocampus, midbrain, or cerebellum V<sub>T</sub> Baseline striatal SRTM BP<sub>ND</sub> did not differ significantly from DVR - 1 except for <sup>18</sup>F-FPSCH when using a 60-min scan and midbrain as the reference region, whereas Bland-Altman analysis found a smaller bias for <sup>18</sup>F-FESCH and a 60-min scan. After pretreatment, striatal SRTM BP<sub>ND</sub> did not significantly differ from zero except for <sup>18</sup>F-FPSCH when using hippocampus as the reference region. Striatal SRTM BP<sub>ND</sub> using midbrain or cerebellum as the reference region was significantly lower for <sup>18</sup>F-FPSCH (range, 1.41-2.62) than for <sup>18</sup>F-FESCH (range, 1.64-3.36). <b>Conclusion:</b> Dynamic PET imaging under baseline and blocking conditions determined <sup>18</sup>F-FESCH to be the most suitable PET ligand for quantifying A<sub>2A</sub> receptor expression in the rat brain. Accurate quantification is achieved by a 60-min dynamic PET scan and the use of either cerebellum or midbrain as the reference region.

Medical subject headings